Kornimate/medical-research-clean huggingface dataset:
genetic architecture of avoidant/restrictive food intake disorder

Conditions: ARFID; Eating Disorders; Eating Disorders in Children; Eating, Picky

Summary: the goal of this observational study is to rapidly accelerate knowledge about the biology of avoidant and restrictive food intake disorder or arfid in children ages 7-17 and in adults. the investigators will be evaluating the genetic and environmental origins of arfid. participants will be asked to answer questionnaires online and to submit a saliva sample for dna using a kit that will be mailed to their home.


Eligibility criteria:
inclusion criteria: * meet study criteria for arfid * be willing to submit a saliva sample * have a us mailing address * english-speaking exclusion criteria: * potential other eating disorders
evaluation of the effect of dextro-amphetamin added to physiotherapy in patients after stroke

Conditions: Stroke

Summary: the aim of the study is to evaluate the effect of dextro-amphetamin added to physiotherapy on motor recovery in patients after stroke. the study is a double-blinded placebo-controlled randomised controlled trial. patients after a first-ever ischemic stroke will receive dexamphetamine (10mg) twice per week for a duration of five weeks after a baseline phase of two weeks. the outcome measure focuses on motor recovery and will be assessed: * one and two weeks before study intervention (baseline phase) * five times during the study intervention * one week after study intervention (follow-up) * once after six and twelve months after start of the study intervention (follow-up).


Eligibility criteria:
inclusion criteria: * patients after first-ever ischemic stroke with a clinical relevant paresis of the upper and lower limb (general clinical muscle testing below level four) * correlation of clinical symptoms with a brain imaging (ct or mri) * able to communicate with the neurological examiner and understand the aim/matter of the study (with or without aphasia) * start of the first oral application of the study drug between the fourteenth and 60th day after stroke onset * older than 13 years * given written informed consent (or two independent witnesses) exclusion criteria: * intracranial or (chronic) subdural hemorrhages * any additional neurological or psychiatric illnesses * instable arrythmia * not controlled or treated arterial hypertension * ensured cardioembolic event * anxiolytica, neuroleptica, or alpha-adrenergic antagonists or agonists respectively * certain anticonvulsiva or antihypertonica * manifest hyperthyreosis * dementia or terminal illnesses * epilepsy, phaeochromocytoma or glaucoma * women known to be pregnant or lactating

Keywords: randomised-controlled trial ischemic stroke motor recovery amphetamine motor recovery of patients after a first-ever ischemic stroke
vestibular dysfunction in adult patients with panic disorder with or without agoraphobia

Conditions: Anxiety Disorder; Panic Disorder

Summary: objectives: i. determine whether the prevalence of abnormalities on clinical vestibular (balance) tests is higher in panic disorder with agoraphobia than in uncomplicated panic disorder and nonpanic anxiety disorder. ii. determine whether the prevalence of abnormalities on audiological tests of cochlear or brainstem function is elevated in panic disorder without agoraphobia or nonpanic anxiety disorder. iii. determine whether symptom patterns can be identified that are indicative of vestibular abnormalities in panic disorder. iv. determine whether vestibular dysfunction can be induced by psychosomatic mechanisms.

protocol outline: patients are stratified by otoneurological function (panic disorder without agoraphobia, panic disorder with agoraphobia, anxiety disorder without panic or agoraphobia-like avoidance, and normal controls). patients undergo a psychiatric interview and a structured interview focused on anxiety disorders. physical evaluation is completed. a vestibular evaluation consisting of posturography, rotational testing, and ocular motor screening battery, and positional and caloric testing is completed on all patients. patients then complete an audiological test battery consisting of basic audiological analysis, speech recognition scores, immittance testing, brainstem evoked response, and determination of binaural masking level differences. control patients also complete a hyperventilation-rotational test.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnostically proven panic disorders with or without moderate or severe agoraphobia and anxiety disorders without panic or agoraphobia panic disorder may be accompanied by a secondary axis 1 diagnosis of another disorder, such as depression, generalized anxiety disorder, or dependent, histrionic, or compulsive personality disorder --prior/concurrent therapy-- surgery: no prior ear surgery other: no concurrent medication for medical or psychiatric conditions at least 2 weeks since prior medication no ototoxic drug intake --patient characteristics-- no medical disorders at least 2 weeks since prior upper respiratory tract infection and recovered no history of migraine no head trauma no scoliosis no alcoholism no drug abuse no family history of schizophrenia

Keywords: anxiety disorder disease-related problem/condition neurologic and psychiatric disorders panic disorder rare disease
clinical research on a novel deep-learning based system in pancreatic endoscopic ultrasound scanning

Conditions: Pancreatic Disease

Summary: the goal of this clinical trial is to develop and verify the auxiliary role of the artificial intelligence system in pancreatic ultrasound endoscopic scanning.the main questions it aims to answer are as follows: 1.the comparison of the image recognition accuracy between the artificial intelligence system and the ultrasound endoscopist; 2. whether the artificial intelligence system can improve the efficiency of the pancreatic scanning for the ultrasound endoscopist. participants will undergo pancreatic eus with or without the assistance of the artificial intelligence system.

in this study, pancreatic endoscopic ultrasound scanning videos and images will be collected. first of all, an artificial intelligence system based on deep learning for the navigation and quality control of pancreatic endoscopic ultrasonography will be established. secondly, the artificial intelligence system will be used to identify the site and anatomical structure of the pancreatic ultrasound endoscopy, and the results of the artificial intelligence system's station recognition will be compared with the results of the endoscopist's station recognition. finally, the completeness of standard sites and scanning time of endoscopic-assisted and non-assisted ai systems were compared.

Eligibility criteria:
inclusion criteria: * 1. age ≥18 years old, \<80 years old 2.patients who need endoscopic ultrasonography of pancreas; 3. agree to participate in this study and sign the informed consent form. exclusion criteria: * subjects who meet any of the following criteria cannot be selected for this trial: first. the patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography: 1. poor physical condition, including hemoglobin ≤8.0g/dl, severe cardiopulmonary insufficiency, etc. 2. anesthesia assessment failed 3. pregnancy or breastfeeding 4. in the acute stage of chemical and corrosive injury, it is very easy to cause perforation 5. recent acute coronary syndrome or clinically unstable ischemic heart attack 6. heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\> 90mmhg),patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome. second. disagree to participate in this study. third. there are other problems that do not meet the requirements of this research or that affect the results of the research: 1. pancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand; 2. mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.
comparison of two treatments in intermediate and high-risk acute promyelocytic leukemia (apl) patients to assess efficacy in 1st hematological complete remission and molecular remission

Conditions: Leukemia, Myelocytic, Acute

Summary: the study will compare the efficacy of the 2 treatments in intermediate and high-risk apl patients in achieving first hematological complete remission and molecular remission.


Eligibility criteria:
inclusion criteria: 1. patients with untreated newly diagnosed and genetically proven apl (leukemic cells at diagnosis with the t(15;17) and/or the pml/rarα rearrangement by rt-pcr; the presence of additional cytogenetic lesions is not considered an exclusion criterion) with intermediate and high risk disease. 2. male and female patients age \> 18 years and \< 61 years. exclusion criteria: 1. low risk patients (wbc \ 40 x 109/l). 2. absence of pml-rar α rearrangement in leukemic cells after successful rna extraction and amplification of control gene. 3. pretreated apl.

Keywords: oncology comparison study
expanded access protocol for niraparib in patients with recurrent ovarian cancer

Conditions: Recurrent Ovarian Cancer

Summary: this is an expanded access program (eap) for eligible patients with recurrent ovarian cancer. this program is designed to provide access to niraparib prior to approval by the us food and drug administration (fda). to be eligible, patients with recurrent ovarian cancer following a partial (pr) or complete response (cr) to their most recent platinum-based chemotherapy and must have experienced a pr or cr after the penultimate (next to last) platinum-based chemotherapy for at least 6 months without disease progression after this chemotherapy.

if a patient qualifies for participation in an ongoing niraparib clinical trial or is already participating in a niraparib clinical trial, she will not be able to participate in the eap. ongoing clinical trials for niraparib include: * a phase 3 trial in patients who have received first-line treatment for ovarian cancer (the prima trial, nct # 02655016) * a phase 2 trial in patients who have received multiple lines of treatment for ovarian cancer (the quadra trial, nct # 02354586) * a phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (the topacio trial, nct # 02657889)

Eligibility criteria:
inclusion criteria: 1. histologically diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 2. completion of at least 2 previous courses of platinum-containing chemotherapy. 3. had a cr or pr with duration of response \>/=6 months following penultimate chemotherapy 4. achieved a partial (pr) or complete (cr) tumor response following completion of the last platinum-containing chemotherapy \[minimum of 4 cycles\] 5. patients previously treated with parp inhibitors are eligible 6. eastern cooperative oncology group (ecog, http://ecog-acrin.org/) performance status 0 or 1 7. adequate organ function \[absolute neutrophil count (anc) ≥ (greater than or equal to) 1,500/µl; platelets ≥ (greater than or equal to) 100,000/µl; hemoglobin ≥ (greater than or equal to) 9 g/dl\] 8. able to take oral medications 9. women should not be pregnant at the beginning of the treatment and women or childbearing potential should not become pregnant while on niraparib 10. patient should start treatment with niraparib no later than 12 weeks after completion of final dose of the platinum-containing chemotherapy exclusion criteria: 1. persistent ≥grade 2 hematologic toxicity from prior cancer therapy 2. known hypersensitivity to the components of niraparib 3. patient is pregnant or breast feeding, or expecting to conceive children within the projected duration of the program treatment 4. patient has uncontrolled hypertension
a study to assess the duration of action of pf-03526299 in asthmatic subjects following allergen challenge

Conditions: Asthma

Summary: the purpose of this study is to find out how long the effect of pf-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen

to assess duration of action of the compound in suppressing the early and late allergen response in asthma patients

Eligibility criteria:
inclusion criteria: * male and/or female subjects between the ages of 18 and 60 years, inclusive. * a history or diagnosis of asthma that requires the use of beta 2 agonist bronchodilators (eg salbutamol). * women who could become pregnant must use appropriate birth control throughout the study and pregnancy tests must be negative on entering the study and prior to dosing in the clinic. exclusion criteria: * subjects who have been hospitalized for the treatment of asthma within three months prior to study entry, or have been hospitalized more than twice in last 12 months. * subjects who have experienced a lower respiratory tract infection (eg bronchitis or pneumonia) or significant asthma instability in the 4 weeks prior to study entry. * severe additional disease other than asthma

Keywords: asthma duration of action allergen challenge
type 1 together: a peer mentorship program to bolster use of cgm

Conditions: Diabetes Mellitus, Type 1

Summary: the goal of this clinical trial is to evaluate a new way of helping adolescents with type 1 diabetes consistently use continuous glucose monitoring systems (cgm). families who participate will be assigned by chance to one of two groups. one group will continue to see their endocrinology provider who can give recommendations on ways to use cgm. the other group will be in our type 1 together program for 6 months. this will include: 1. monthly meetings with a community health worker with expertise in type 1 diabetes self-management, 2. access to cgm-specific educational resources hosted on a mobile app, and 3. meeting at least monthly with a mentor family who will provide mentorship on using cgm consistently. the main questions the study aims to answer are: 1. do families like the type 1 together program? 2. do more families in the type 1 together program have better attitudes towards cgm, use cgm more consistently, and have lower hba1c? 3. does the type 1 together program reduce racial and ethnic differences in attitudes towards cgm, consistent use of cgm, and hba1c?


Eligibility criteria:
inclusion criteria: * 12 to 17 years old * diagnosed with type 1 diabetes for at least 6 months * does not use cgm or uses cgm \< 24 out of the past 30 days * use cgm 24 to 30 of the past 30 days but most recent hba1c was 9% or more * able to read and write in english exclusion criteria: * type 1 diabetes due to other medical condition (e.g., cystic fibrosis) * intellectual disability * severe psychiatric comorbidities
muscles strength and gait parameteres after tka

Conditions: Arthritis Knee; Gait Biomechanics; Total Knee Arthroplasty; Muscle Strength; Osteoarthritis

Summary: total knee arthroplasty (tka) is actually the most effective treatment option for patients with end-stage osteoarthritis (oa). however, nearly 20% of patients who underwent tka remain unsatisfied with their clinical outcome. investigating modifiable factors that limit knee functioning following tka we may notice the significance of lower limb muscles strength. gait pattern is also affected by oa, as arthritic knee joint cannot provide proper range of motion (rom) and stability.therefore any deviation in biomechanics should be noticed and analyzed. after tka patients' physical function may change, but the study should be conducted to prove whether it improves or not. patient-reported outcome defined by oks (oxford knee score) and fjs (forgotten joint score) questionnaires will be evaluated.


Eligibility criteria:
inclusion criteria: * iii° or iv° grade knee osteoarthritis * age over 50 * patients with signed consent exclusion criteria: * undergone total hip replacement * previous femur fracture in anamnesis * undergone corrective osteotomy * active/ chronic neoplastic disease * significant deformation of lower limb axis * mental disorders * muscular disorders
predictive factors in response to inhaled corticoids in chronic cough

Conditions: Healthy

Summary: the hypothesis is that a high fractional exhaled nitric oxide can predict the response to inhaled corticoids in chronic cough.


Eligibility criteria:
inclusion criteria: * chronic cough exclusion criteria: * active smoker * treated by corticoids during the previous month * use of angiotensin-converting-enzyme inhibitor
evaluation of retinal microvascular change that may develop in after open globe injury

Conditions: Eye Injury Trauma

Summary: the aim of this study is to evaluate posterior segment changes in the non-traumatic eye after open globe injury.

globe injuries can be classified as either closed- or open-globe injuries, based on the integrity of the sclera and cornea. open-globe injury (ogi) is characterized by a full-thickness wound of the ocular wall. as one of the most severe forms of ocular trauma, open-globe injury (ogi) causes significant vision loss. timely and meticulous repair of these injuries can improve patient outcomes. ogi by rupture often occurs at the weakest point of the eye wall, which may or may not be at the actual injury site. the rupture site is most commonly found in the sclera concentric to the limbus, just posterior to the insertion of the extraocular muscles. after trauma, changes may occur in the non-trauma eye. retinal and choroidal circulation may change as a result of adaptation mechanisms. in this study, we evaluated the vascular densities of the control group and post-traumatic non-trauma eye.

Eligibility criteria:
inclusion criteria: * be over 18 years old * unilateral eye injury exclusion criteria: * be under the age of 18 * usage of systemic drugs or topical ocular drops * bilateral eye injury * having systemic disease, having ocular pathology that may decrease visual acuity

Keywords: eye injury trauma open globe injury optical coherence tomography
study to evaluate overall survival in japanese patients with hr+/her2- advanced breast cancer treated with palbociclib plus letrozole

Conditions: Breast Cancer

Summary: this is a retrospective, multicenter, observational study in japan. the primary objective is to evaluate overall survival (os) in japanese patients with hr+/her2- advanced breast cancer who have been treated with palbociclib plus letrozole. this observational study was planned as follow-up study of japanese phase 2 study of palbociclib (nct01684215, phase 2 portion of a5481010 study).


Eligibility criteria:
inclusion criteria: 1. participated, treated with palbociclib plus letrozole in j-ph2, and was under follow-up for survival at the study completion of j-ph2. 2. for patients who are still alive and have routine visits to the study site, evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. for patients who are still alive and had been transferred to another hospital, evidence that the patient has been informed of all pertinent aspects of the study and oral or written informed consent is obtained. for patients who had already passed away, the conduct of this study will be disclosed, and the patients' legally acceptable representatives will be guaranteed an opportunity to refuse data collection for the patients in accordance with the ethical guidelines for medical and health research involving human subjects exclusion criteria: 1. there are no exclusion criteria for this study.

Keywords: retrospective multicenter observational study japan hr+/her2- advanced breast cancer palbociclib overall survival
intensive motor rehabilitation with technology for patients with central neurological disease

Conditions: Stroke; Spinal Cord Injuries; Chronic Disease

Summary: this project will consist of 1 large clinical trial with 2 core concepts: (1) clinical benefits of an intensive rehabilitation programme using advanced technology, compared to the control group; (2) a full health economic evaluation combined with model-based estimation of costs and benefits.


Eligibility criteria:
inclusion criteria: 1. voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures; 2. a diagnosis of central neurological disease, made by a specialist. conditions may include stroke or spinal cord injury: 1. stroke: participants must have received a diagnosis of stroke for the first time, have been diagnosed at least 3 months ago, and live at home. 2. sci: participants have a rating a, b, c or d on the american spinal injury association (asia) measurement scale, which refers to patients with complete or incomplete impairment. all levels of sci can be included, if there is a clear patient need linked to the upper and/or lower extremities. 3. at least 3 months post discharge from hospital/rehabilitation centre, living at home; 4. having a maximum recovery of 85% of independence in daily functioning (fim/scim); 5. had a normal functional state prior to the pathology: a pre-pathology barthel index \> 85/100; 6. unilateral or bilateral weakness of the affected upper or lower limbs (no maximum score in all affected limbs = motricity index: score 5 on 3/3 segments) 7. having the clinical opportunity to engage in exercise therapy with available technology, assessed by a specialist; 8. age of \> 18 years; 9. sufficient cognitive ability to understand the games and give informed consent, assessed by a specialist;. exclusion criteria: 1. having other neurological or musculoskeletal conditions that may affect the protocol, assessed by a specialist; 2. no ability to initiate movements against gravity in the upper and lower limbs; 3. severe visual impairment, communication, cognitive and language formation problems that would prevent the intervention and measurement process, assessed by a specialist; 4. any disorder, which in the investigator's opinion might the compromise participant's safety or compliance with the cip; 5. female who is pregnant, breast-feeding.

Keywords: rehabilitation intensive technology